BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. has announced an initial investment in cryptocurrencies to diversify its treasury and explore acquisition opportunities.
The company acquired 10.5 Bitcoin (BTC) and 300 Ethereum (ETH) at a cost of around $2.6 million. This move is part of their effort to enhance their treasury structure and improve transaction flexibility. Cryptocurrencies now constitute approximately 43.6% of LIXTE’s treasury assets. Recently, the Board sanctioned raising the cryptocurrency allocation limit to 50%.
“The inclusion of Bitcoin and Ethereum in our treasury underscores our strategy to establish a balanced digital asset approach alongside our cash reserves,” stated Geordan Pursglove, Chairman and CEO of LIXTE. “This diversification allows us to better navigate the digital economy and stay adaptable for future growth. We will continually evaluate responsible avenues to integrate cryptocurrency into our business framework and treasury management.”
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc is focused on cancer drug discovery and the commercialization of cancer therapies. The company’s primary drug candidate, LB-100, is a first-in-class PP2A inhibitor showing promise in oncology treatments.
LIXTE’s innovative cancer approaches are backed by a robust patent portfolio, with clinical trials underway for various cancers, including Ovarian Clear Cell Carcinoma and Advanced Soft Tissue Sarcoma. For additional details, visit www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains forward-looking statements as defined under the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements involve predictions about financial positions, business strategies, and objectives. They include terms like “intend,” “believe,” “estimate,” and “expect.” However, actual outcomes may vary considerably due to various risks including regulatory changes, competition, and market conditions.
Readers are encouraged to review the risk factors detailed in the Company’s SEC filings at https://www.sec.gov. The Company intends to update or revise these statements only as required by law.
For more information about LIXTE, contact:
[email protected]
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations [email protected]
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
